Ing. Ivana Ježíšková, Ph.D.
Researcher, Department of Internal Medicine, Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
phone: | +420 532 23 4628 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 93
2022
-
Somatic mutations in myeloid transcription factors and in activated signaling pathway, but not in epigenetic modifier pathway, predict the risk of tratment failure and progression to advanced phase in chronic myeloid leukemia
Year: 2022, type: Conference abstract
-
Současná role cytogenomiky v diagnostice a prognostické stratifikaci hematologických malignit.
Year: 2022, type: Conference abstract
-
The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
Year: 2022, type: Conference abstract
-
Využití mutací v genu CEBPA pro sledování minimální reziduální nemoci pomocí sekvenování nové generace u pacientů s akutní myeloidní leukémií
Year: 2022, type: Conference abstract
2021
-
Acute myeloid leukemia regression induced by palbociclib and ponatinib in patient –derived xenograft model.
Year: 2021, type: Conference abstract
-
Diferenciální diagnostika eozinofilií v letech 2015-2020 na IHOK FN Brno.
Year: 2021, type: Conference abstract
-
Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).
Year: 2021, type: Conference abstract
-
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients
LEUKEMIA & LYMPHOMA, year: 2021, volume: 62, edition: 5, DOI
-
Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
Year: 2021, type: Conference abstract
-
HALF: Multicentrická akademická studie fáze II vysazující inhibitory tyrozinkináz po dvoustupňové redukci dávky u pacientů s chronickou myeloidní leukémií – první výsledky.
Year: 2021, type: Conference abstract